New blockbuster vaccine boosts sales and profits at drugs giant GSK

A NEW blockbuster vaccine has boosted sales and profits at drugs giant GSK. Last May, Arexvy became the world’s first approved vaccine for older sufferers of respiratory syncytial virus (RSV). More…

Pfizer's COVID cash powers a 'marketing machine' on the hunt for new supernovas

Money - latest news and stories

GSK's R&D Head Hal Barron Will Take Center Stage This Week With Program Review

GlaxoSmithKline tops its peers with $7.16B in 2017 vaccine sales

GSK lifts long-term outlook following launch of blockbuster vaccine in 2023 - MarketWatch

GSK vaccine for shingles help group lift sales and profits

The top 5 vaccine companies by 2017 revenue

Pharma giants in 2023: Revenue insights by top product categories

Shell sees profits tumble 29% to £22.4billion — but announces

Top 10 most anticipated drug launches of 2023

GSK lifts long-term outlook amid RSV sales and new drugs

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

The top 10 most profitable pharma companies in 2021